跳转至内容
Merck
CN

SML1796

阿扎那韦

≥98% (HPLC), HIV protease inhibitor, powder

别名:

1,14-二甲基（3S，8S，9S，12S）-3,12-双（1,1-二甲基乙基）-8-羟基-4,11-二氧代-9-（苯甲基）-6-[[4- （2-吡啶基）苯基]甲基] -2,5,6,10,13-五叠氮丙二酸酯, BMS-232632

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C38H52N6O7
化学文摘社编号:
198904-31-3
分子量:
704.86
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD08435966

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

阿扎那韦, ≥98% (HPLC)

form

powder

InChI

1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1

SMILES string

O=C(N[C@@H](C(C)(C)C)C(N[C@H]([C@H](CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)O)CC3=CC=CC=C3)=O)OC

InChI key

AXRYRYVKAWYZBR-GASGPIRDSA-N

assay

≥98% (HPLC)

optical activity

[α]/D -41 to -49°, c = 0.1 in ethanol

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

−20°C

Quality Level

100

相关类别

General description

阿扎那韦抑制人免疫缺陷病毒中 gag 和 gag-pol 多蛋白的裂解。它被肝脏中的细胞色素 P450 吸收和代谢。它具有最小的副作用，并且对胰岛素敏感性和血清脂质谱没有影响。

Biochem/physiol Actions

阿扎那韦是一种抗病毒 HIV 蛋白酶抑制剂。

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H319

Hazard Classifications

Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000186835
0000186834
0000186834
0000186835
0000138102

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Daniel W Cole et al.
Experimental cell research, 382(1), 111386-111386 (2019-05-11)
Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by
Saif Ahmad Khan et al.
Pharmaceutics, 12(11) (2020-11-12)
Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS. The utilization of nanostructured lipid carriers (NLCs) in conjunction with the premeditated use of
Atazanavir
Croom KF, et al.
Drugs, 69(8), 1107-1140 (2009)
Jose R Castillo-Mancilla et al.
The Journal of antimicrobial chemotherapy, 71(6), 1609-1618 (2016-02-20)
The multinational PEARLS (ACTG A5175) study, conducted mainly in resource-limited settings, identified an increased treatment failure rate among HIV-infected individuals randomized to once-daily unboosted atazanavir, didanosine-EC, and emtricitabine compared with efavirenz-based regimens. We evaluated associations between selected human genetic polymorphisms
Masayuki Amano et al.
Antimicrobial agents and chemotherapy, 63(7) (2019-05-08)
There is currently no specific therapeutics for the HIV-1-related central nervous system (CNS) complications. Here we report that three newly designed CNS-targeting HIV-1 protease inhibitors (PIs), GRL-083-13, GRL-084-13, and GRL-087-13, which contain a P1-3,5-bis-fluorophenyl or P1-para-monofluorophenyl ring, and P2-bis-tetrahydrofuran (bis-THF)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持